title: Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.
abstract: OBJECTIVE
  We conducted a pooled post hoc analysis (RESOLUTE All Comers and RESOLUTE International) of patients who had the Resolute® zotarolimus-eluting stent (R-ZES) implanted in revascularised total occlusions (TO) compared with patients treated with R-ZES for non-occluded lesions.
  
  
  RESULTS
  Patients were divided into three groups: chronic TO (CTO; n=256), non-chronic TO (n=292), and no occlusion (n=2,941). Clinical and safety outcomes assessed through two years included target lesion failure (TLF: cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation) and Academic Research Consortium definite or probable stent thrombosis. The rate of TLF at two years was not significantly different among patients in the CTO (9.1%), TO (9.8%), and no occlusion (10.4%) groups (log-rank p=0.800); neither were the components of TLF. Definite or probable stent thrombosis occurred more frequently in the TO group (2.8% vs. 1.2% in the CTO and 1.1% in the group with no occlusion, p=0.027). There were 10 late and six very late stent thrombosis events.
  
  
  CONCLUSIONS
  Apart from a higher rate of stent thrombosis in patients with TO, patients with totally occluded coronary arteries who receive revascularisation with an R-ZES have clinical outcomes comparable to those who receive a similar stent in non-occluded lesions.
authors.affiliation: Cardiac Catheterisation Laboratory, Rigshospitalet, Copenhagen, Denmark.
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbæk
authors.forename: Lene
authors.initials: L
authors.lastname: Holmvang
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
authors.forename: Franz R
authors.initials: FR
authors.lastname: Eberli
authors.forename: Pieter
authors.initials: P
authors.lastname: Stella
authors.forename: Pawel E
authors.initials: PE
authors.lastname: Buszman
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
authors.forename: Petr
authors.initials: P
authors.lastname: Widimský
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Belardi
authors.forename: Sigmund
authors.initials: S
authors.lastname: Silber
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage; D002908:Chronic Disease; D054059:Coronary Occlusion / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents; D053208:Kaplan-Meier Estimate; D009203:Myocardial Infarction / Q000209:etiology; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation / Q000401:mortality; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors; D016896:Treatment Outcome; D064887:Observational Studies as Topic; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic
chemical_list: D002317:Cardiovascular Agents; D020123:Sirolimus; C489443:zotarolimus